Cellectis (NASDAQ:CLLS) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.27) by 29.63 percent. This is a 13.64 percent increase over losses of $(0.22) per share from the same period last year. The company reported quarterly sales of $6.904 million which missed the analyst consensus estimate of $13.225 million by 47.80 percent. This is a 62.05 percent decrease over sales of $18.193 million the same period last year.